

Special Issue

Advances in Polycystic Ovary Syndrome Research: From Molecular Mechanisms to Therapeutic Strategies

Message from the Guest Editor

Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders of women of reproductive age, which negatively affects the reproductive and mental health of women. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary morphology are diagnostic criteria of PCOS. While obesity, increased cardiovascular risk factors, insulin resistance, hyperinsulinism, and type 2 diabetes mellitus are common symptoms among women with PCOS, they are not required criteria for diagnosis. Since PCOS leads to infertility, early diagnosis and treatments are critical, particularly at the extreme ends of the reproductive lifespan. Therefore, in recent years, understanding the underlying mechanisms, diagnosis, and clinical management of PCOS have become increasingly significant. This Special Issue of “Advances in Polycystic Ovary Syndrome Research” will include original research articles and review articles addressing recent advances in our knowledge about etiology, pathophysiology and diagnosis of PCOS as well as advances in therapeutic options for managing PCOS.

Guest Editor

Dr. Ebrahim Asadi

Department of Biology, University of Saskatchewan, Saskatoon, SK S7N 5E2, Canada

Deadline for manuscript submissions

closed (31 May 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/161656

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).